just published an article featuring the interview with Exogenus’ CEO and CSO, Joana Correia, discussing the disparity in funding opportunities seen in Europe vs USA. The article, which also quotes Antonin de Fougerolles (Evox Therapeutics, CEO) and Douglas Williams(Codiak Biosciences, CEO), highlights the astounding differencein behavior between European and American venture capitalswhen we talk about funding for development of exosomes therapies, arguing that Europe may be left behind in the race for exosomebased therapeutic innovations. Preparing for a Series A round later this year, Exogenus is proud to once again stand out as one of the few companies in the field, leading the way towards exosomebased care for patients with high unmet needs. Click here to read article.